BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33709965)

  • 1. Immunophenotypical characterization of paraneoplastic neurological syndrome patients: a multicentric study.
    Lorusso L; Precone V; Hart IK; Giometto B; Pezzani R; Ngonga GK; Ngonga GKNK; Paolacci S; Ferrari D; Ricevuti G; Marshall E; Bertelli M
    J Biosci; 2021; 46():. PubMed ID: 33709965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer, Hu antibodies and paraneoplastic neurological syndromes.
    Storstein A; Raspotnig M; Vitaliani R; Giometto B; Graus F; Grisold W; Honnorat J; Vedeler CA
    J Neurol; 2016 May; 263(5):1001-1007. PubMed ID: 27007485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Non-classical" paraneoplastic neurological syndromes associated with well-characterized antineuronal antibodies as compared to "classical" syndromes - More frequent than expected.
    Berger B; Bischler P; Dersch R; Hottenrott T; Rauer S; Stich O
    J Neurol Sci; 2015 May; 352(1-2):58-61. PubMed ID: 25824848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single center retrospective study of paraneoplastic neurological syndromes with positive onconeural antibodies.
    Fu P; He L; Tang N; Nie Q; Li Z
    J Clin Neurosci; 2021 Jul; 89():336-342. PubMed ID: 34119290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurological paraneoplastic syndromes in lung cancer patients.
    Stefens-Stawna P; Piorunek T; Gabryel-Batura H; Kozubski W; Michalak S
    Adv Exp Med Biol; 2013; 756():333-9. PubMed ID: 22836651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology of paraneoplastic neurological syndromes: a population-based study.
    Vogrig A; Gigli GL; Segatti S; Corazza E; Marini A; Bernardini A; Valent F; Fabris M; Curcio F; Brigo F; Iacono D; Passadore P; Rana M; Honnorat J; Valente M
    J Neurol; 2020 Jan; 267(1):26-35. PubMed ID: 31552550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies.
    Ariño H; Höftberger R; Gresa-Arribas N; Martínez-Hernández E; Armangue T; Kruer MC; Arpa J; Domingo J; Rojc B; Bataller L; Saiz A; Dalmau J; Graus F
    JAMA Neurol; 2015 Aug; 72(8):874-81. PubMed ID: 26099072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positivity of serum "classical" onconeural antibodies in a series of 2063 consecutive patients with suspicion of paraneoplastic neurological syndrome.
    Gromadzka G; Karlińska AG; Łysiak Z; Błażejewska-Hyżorek B; Litwin T; Członkowska A
    J Neuroimmunol; 2013 Jun; 259(1-2):75-80. PubMed ID: 23642452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects.
    Storstein A; Vedeler CA
    Adv Clin Chem; 2007; 44():143-85. PubMed ID: 17682342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenesis of paraneoplastic neurological syndromes].
    Tanaka K
    Brain Nerve; 2010 Apr; 62(4):309-18. PubMed ID: 20420170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Paraneoplastic neurological syndrome and autoantibodies].
    Hayashi Y; Inuzuka T
    Brain Nerve; 2013 Apr; 65(4):385-93. PubMed ID: 23568986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paraneoplastic neurological syndromes with onconeural antibodies: A single center retrospective study.
    Oliveira V; Videira G; Samões R; Carneiro P; Neves E; Santos E
    J Neurol Sci; 2020 Nov; 418():117103. PubMed ID: 32877801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paraneoplastic neurological syndromes in lung cancer patients with or without onconeural antibodies.
    Raspotnig M; Vedeler C; Storstein A
    J Neurol Sci; 2015 Jan; 348(1-2):41-5. PubMed ID: 25467140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Paraneoplastic neurological syndromes in 2008].
    Honnorat J
    Rev Neurol (Paris); 2009 May; 165 Suppl 3():S59-65. PubMed ID: 19524096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Onconeuronal and antineuronal antibodies in patients with neoplastic and non-neoplastic pulmonary pathologies and suspected for paraneoplastic neurological syndrome.
    Michalak S; Cofta S; Piatek A; Rybacka J; Wysocka E; Kozubski W
    Eur J Med Res; 2009 Dec; 14 Suppl 4(Suppl 4):156-61. PubMed ID: 20156748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid study in paraneoplastic syndromes.
    Psimaras D; Carpentier AF; Rossi C;
    J Neurol Neurosurg Psychiatry; 2010 Jan; 81(1):42-5. PubMed ID: 19324868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onconeural antibodies in patients with neurological symptoms: detection and clinical significance.
    Raspotnig M; Vedeler CA; Storstein A
    Acta Neurol Scand Suppl; 2011; (191):83-8. PubMed ID: 21711262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A large screen for paraneoplastic neurological autoantibodies; diagnosis and predictive values.
    Seluk L; Taliansky A; Yonath H; Gilburd B; Amital H; Shoenfeld Y; Kivity S
    Clin Immunol; 2019 Feb; 199():29-36. PubMed ID: 30543927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onconeural antibodies are essential to diagnose paraneoplastic neurological syndromes.
    Honnorat J
    Acta Neurol Scand Suppl; 2006; 183():64-8. PubMed ID: 16637934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
    Stich O; Klages E; Bischler P; Jarius S; Rasiah C; Voltz R; Rauer S
    Acta Neurol Scand; 2012 May; 125(5):326-31. PubMed ID: 21751968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.